The EMA approved the first gene therapy agent in 2012 – for lipoprotein lipase deficiency. Might gene therapies for ophthalmic disease reach the wards any time soon?
By Irv Arons and Mark Hillen
Log in or sign up for FREE to read this article in full and gain access to The Ophthalmologist’s entire content archive.
or sign in with: